Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

tgTWE2 Oct. 18 at 5:23 AM

?? High-conviction cluster — risk-defined entries only! ???? ?? Portfolio: $BIIB $C $QCOM $VRTX $MRNA ?? Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. BIIB shows relative strength; C is base-building; QCOM is a stealth accumulator; VRTX offers sector exposure; MRNA provides stability. ?? Execution: Execution: define stop levels, use partial profit-taking on initial leg. ?? ???? #AlphaHunt #Tactical ???? ?? Source: https://stocktwits.com/MichaelFreeman6940/message/632828614

0 · Reply

StockAutoPro Oct. 18 at 3:49 AM

$BIIB: Buy target $151.89 Sell target $161.58 Strong Alzheimer's drug potential may drive significant sector growth.

0 · Reply

lecorb Oct. 17 at 1:06 PM

$SNY Sanofi and Insmed among winners of EU drug recommendations this week $INSM $BIIB $REGN $AGIO & More. https://seekingalpha.com/news/4505183-sanofi-insmed-among-winners-chmp-recommendations?mailingid=42050924&messageid=2900&position=rta_news_most_popular_main_0_title&serial=42050924.22569&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=42050924.22569

0 · Reply

MoneyGroupLLC Oct. 17 at 12:00 AM

Enter: $BIIB NOV 07 2025 $144 CALLS Buy in Price: $8.80 - $11.05 Take Profit: $20.77 Stop Bleeding: $9.72 ROI Potential: 88% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

SuperGreenToday Oct. 16 at 5:19 PM

$BIIB Share Price: $143.33 Contract Selected: Nov 07, 2025 $144.0 Calls Buy Zone: $4.93 – $6.09 Target Zone: $7.97 – $9.75 Potential Upside: 53% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SR_JACK Oct. 14 at 9:07 PM

Biogen Expects Q3 Charge Of $0.01 Per Share Due To $2M In Acquired R&D, Upfront, And Milestone Expenses, Impacting Both GAAP And Non-GAAP Earnings $BIIB

0 · Reply

JarvisFlow Oct. 14 at 7:15 PM

Scotiabank updates rating for Biogen ( $BIIB ) to Sector Outperform, target set at 304 → 275.

1 · Reply

JarvisFlow Oct. 14 at 7:11 PM

RBC Capital updates rating for Biogen ( $BIIB ) to Outperform, target set at 213 → 208.

0 · Reply

JarvisFlow Oct. 14 at 7:07 PM

RBC Capital has updated their rating for Biogen ( $BIIB ) to Outperform with a price target of 340.

0 · Reply

JarvisFlow Oct. 14 at 7:01 PM

Needham has updated their rating for Biogen ( $BIIB ) to Buy with a price target of 321.

0 · Reply

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”

Oct 9, 2025, 4:30 PM EDT - 9 days ago

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Oct 9, 2025, 4:30 PM EDT - 9 days ago

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

STOK

Oct 9, 2025, 10:54 AM EDT - 9 days ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 6, 2025, 4:30 PM EDT - 12 days ago

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

Oct 6, 2025, 1:29 PM EDT - 12 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BMY GILD

Oct 3, 2025, 8:50 AM EDT - 15 days ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 1, 2025, 5:48 PM EDT - 17 days ago

‘Fast Money' traders talk opportunities in health care stocks

AMGN BMY IBB LLY MRK MRNA PFE

Sep 28, 2025, 7:30 PM EDT - 19 days ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

Sep 26, 2025, 12:21 PM EDT - 22 days ago

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

ABBV LLY MRK PFE BMY

Sep 24, 2025, 2:17 PM EDT - 24 days ago

Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 24, 2025, 7:30 AM EDT - 24 days ago

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia

Sep 23, 2025, 4:41 PM EDT - 25 days ago

US FDA declines to approve higher-dose of Biogen's genetic disorder drug

Sep 23, 2025, 4:30 PM EDT - 25 days ago

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

Sep 18, 2025, 7:40 AM EDT - 4 weeks ago

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Sep 17, 2025, 4:30 PM EDT - 4 weeks ago

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Sep 8, 2025, 6:51 PM EDT - 5 weeks ago

Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 2:09 PM EDT - 6 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN GILD JNJ LLY MRK

Sep 2, 2025, 7:30 PM EDT - 6 weeks ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Sep 2, 2025, 7:00 AM EDT - 6 weeks ago

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Sep 2, 2025, 7:00 AM EDT - 6 weeks ago

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

STOK

Sep 2, 2025, 4:54 AM EDT - 6 weeks ago

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

NIO NVDA

Aug 29, 2025, 5:08 PM EDT - 7 weeks ago

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

Aug 29, 2025, 5:00 PM EDT - 7 weeks ago

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Aug 28, 2025, 2:16 PM EDT - 7 weeks ago

FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi

Aug 25, 2025, 7:00 AM EDT - 7 weeks ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

STOK

Aug 25, 2025, 7:00 AM EDT - 7 weeks ago

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Aug 25, 2025, 3:00 AM EDT - 7 weeks ago

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

Aug 11, 2025, 7:00 AM EDT - 2 months ago

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Aug 11, 2025, 7:00 AM EDT - 2 months ago

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

STOK

Aug 2, 2025, 9:15 AM EDT - 2 months ago

Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio

Aug 1, 2025, 8:31 AM EDT - 2 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 2 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 31, 2025, 2:24 PM EDT - 2 months ago

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 6:17 AM EDT - 2 months ago

Biogen raises annual profit forecast on strong demand for rare disease drugs

Jul 30, 2025, 11:00 AM EDT - 2 months ago

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

Jul 30, 2025, 8:12 AM EDT - 2 months ago

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Jul 25, 2025, 7:20 AM EDT - 3 months ago

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

Jul 21, 2025, 7:30 PM EDT - 3 months ago

Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025

Jul 21, 2025, 2:25 PM EDT - 3 months ago

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Jul 21, 2025, 7:41 AM EDT - 3 months ago

Biogen to invest $2 billion more in North Carolina

Jul 21, 2025, 7:30 AM EDT - 3 months ago

Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary

Jul 10, 2025, 7:00 AM EDT - 3 months ago

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

STOK

Jul 10, 2025, 7:00 AM EDT - 3 months ago

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

STOK

Jun 30, 2025, 7:30 AM EDT - 3 months ago

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Jun 27, 2025, 10:00 AM EDT - 4 months ago

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Jun 25, 2025, 7:30 AM EDT - 4 months ago

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Jun 22, 2025, 10:27 PM EDT - 4 months ago

Biogen: Investors Are Missing The Bigger Picture

Jun 18, 2025, 11:13 AM EDT - 4 months ago

20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks

AAPL AIG AMAT AZO BK BKNG C

tgTWE2 Oct. 18 at 5:23 AM

0 · Reply

StockAutoPro Oct. 18 at 3:49 AM

$BIIB: Buy target $151.89 Sell target $161.58 Strong Alzheimer's drug potential may drive significant sector growth.

0 · Reply

lecorb Oct. 17 at 1:06 PM

0 · Reply

MoneyGroupLLC Oct. 17 at 12:00 AM

Enter: $BIIB NOV 07 2025 $144 CALLS Buy in Price: $8.80 - $11.05 Take Profit: $20.77 Stop Bleeding: $9.72 ROI Potential: 88% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

SuperGreenToday Oct. 16 at 5:19 PM

0 · Reply

SR_JACK Oct. 14 at 9:07 PM

Biogen Expects Q3 Charge Of $0.01 Per Share Due To $2M In Acquired R&D, Upfront, And Milestone Expenses, Impacting Both GAAP And Non-GAAP Earnings $BIIB

0 · Reply

JarvisFlow Oct. 14 at 7:15 PM

Scotiabank updates rating for Biogen ( $BIIB ) to Sector Outperform, target set at 304 → 275.

1 · Reply

JarvisFlow Oct. 14 at 7:11 PM

RBC Capital updates rating for Biogen ( $BIIB ) to Outperform, target set at 213 → 208.

0 · Reply

JarvisFlow Oct. 14 at 7:07 PM

RBC Capital has updated their rating for Biogen ( $BIIB ) to Outperform with a price target of 340.

0 · Reply

JarvisFlow Oct. 14 at 7:01 PM

Needham has updated their rating for Biogen ( $BIIB ) to Buy with a price target of 321.

0 · Reply

JarvisFlow Oct. 14 at 7:00 PM

Needham updates rating for Biogen ( $BIIB ) to Buy, target set at 321.

0 · Reply

JarvisFlow Oct. 14 at 6:59 PM

Needham has adjusted their stance on Biogen ( $BIIB ), setting the rating to Buy with a target price of 321.

0 · Reply

JarvisFlow Oct. 14 at 6:57 PM

Needham updates rating for Biogen ( $BIIB ) to Buy, target set at 305.

0 · Reply

MoneyGroupLLC Oct. 14 at 6:13 PM

Enter: $BIIB NOV 07 2025 $148 CALLS Buy in Price: $8.20 - $9.90 Take Profit: $23.66 Stop Bleeding: $8.71 ROI Potential: 139% Exit Within: 1 Weeks https://moneygroup.us/alerts

0 · Reply

theDIOyears Oct. 13 at 12:48 PM

$XTNT $BIIB $PHAT $BVS $LGCY In traders jail for the next 90 days. Pray for me.

1 · Reply

pkmatov Oct. 13 at 8:59 AM

$BIIB $OKLO

0 · Reply

BostonNorth Oct. 12 at 7:46 PM

$SPRY $NDAQ $BIIB @Stocktwits

1 · Reply

MoneyGroupLLC Oct. 12 at 4:27 PM

Enter: $BIIB OCT 31 2025 $147 CALLS Buy in Price: $3.05 - $6.10 Take Profit: $6.10 Stop Bleeding: $2.68 ROI Potential: 100% Exit Within: 88 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Oct. 11 at 3:29 PM

Enter: $BIIB OCT 31 2025 $147 CALLS Buy in Price: $3.05 - $6.10 Take Profit: $6.10 Stop Bleeding: $2.68 ROI Potential: 100% Exit Within: 88 Minutes https://moneygroup.us/alerts

0 · Reply

Bulltard69 Oct. 11 at 1:57 PM

$OKLO congrats OKLO bulls. You just surpassed $BIIB in market cap. Biogen only does $10B of revenue a year. And they are just a boring pharmaceutical company, not a super cool, hip, nuclear startup. Oklo makes $0 revenue a year but they have super sweet 3d rendering of a fission plant that *Might* start generating revenue by 2030. Have you seen that yet?? #winning

1 · Reply

SuperGreenToday Oct. 11 at 1:30 AM

$BIIB Share Price: $146.61 Contract Selected: Nov 07, 2025 $150 Calls Buy Zone: $5.10 – $6.30 Target Zone: $8.91 – $10.89 Potential Upside: 65% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

JarvisFlow Oct. 10 at 5:36 PM

Morgan Stanley has updated their rating for Biogen ( $BIIB ) to Equal-Weight with a price target of 149.

0 · Reply

Market Cap	20.86B
Revenue (ttm)	9.68B
Net Income (ttm)	1.63B
EPS (ttm)	N/A
PE Ratio	8.97
Forward PE	9.09
Profit Margin	16.87%
Debt to Equity Ratio	0.36

Volume	1,010,000
Avg Vol	1,608,614
Day's Range	N/A - N/A
Shares Out	146.62M
Stochastic %K	10%
Beta	0.13
Analysts	Sell
Price Target	$172.36